10-K: Health Catalyst Reports Wider 2025 Loss Amid Goodwill Impairment

Health Catalyst, Inc. reported a significant net loss of $178.0 million in 2025, primarily driven by a $105.4 million goodwill impairment, despite a modest 1% revenue increase to $311.1 million.

Summary

• Total revenue for 2025 increased by 1% to $311.1 million, up from $306.6 million in 2024.
• Net loss significantly widened to $178.0 million in 2025, compared to $69.5 million in 2024, largely due to a $105.4 million goodwill impairment charge.
• Adjusted EBITDA improved to $41.4 million in 2025, up from $26.1 million in 2024, reflecting revenue growth and cost reduction initiatives.
• Technology revenue grew by 7% to $208.3 million in 2025, while professional services revenue decreased by 8% to $102.9 million.
• The company served 162 Platform Clients as of December 31, 2025, an increase from 130 in 2024, and over 1,000 App Clients.
• Dollar-based Retention Rate (Technology + TEMS) was 93% for 2025, a decrease from 102% in 2024, impacted by DOS to Ignite platform migration churn.
• Workforce reductions were implemented through the January 2025 Restructuring Plan (approximately 4% reduction) and the August 2025 Restructuring Plan (approximately 9% reduction) to optimize cost structure.
• Goodwill and intangible asset impairment charges totaled $110.2 million in 2025, primarily due to declines in stock price and market capitalization.
• The company fully repaid its $230.0 million 2.50% Convertible Senior Notes due 2025 in cash on April 14, 2025.
• Acquired Upfront Healthcare Services, Inc. for $80.0 million in January 2025, Intraprise Health, LLC for $44.9 million in November 2024, Lumeon Ltd. for $39.8 million in August 2024, and Carevive Systems, Inc. for $22.1 million in May 2024.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period marked by significant financial losses due to goodwill impairment and declining retention rates, despite some operational improvements in Adjusted EBITDA and technology revenue growth. The ongoing platform migration and macroeconomic headwinds present considerable near-term uncertainty.

Positives

• Adjusted EBITDA improved significantly to $41.4 million in 2025 from $26.1 million in 2024, indicating better operational efficiency excluding certain non-cash and non-recurring items.
• Technology revenue increased by 7% to $208.3 million in 2025, driven by new and acquired clients, contractual escalators, and expanded support services.
• The company increased its Platform Client count to 162 in 2025 from 130 in 2024, demonstrating market penetration.
• Successful completion of the $230.0 million Convertible Senior Notes repayment in cash at maturity on April 14, 2025.
• Maintained strong application relationships with clients even amidst data platform infrastructure down-selling.
• The company's cybersecurity program incorporates industry-standard frameworks and third-party certifications (HITRUST, SSAE 18 SOC 2, ISO 27001, 9001).
• Management believes the strategic operating plan, focusing on cost efficiency, clinical improvement, and consumer experience, will lead to continued competitive and financial strength.

Negatives

• Net loss widened substantially to $178.0 million in 2025 from $69.5 million in 2024.
• A significant non-cash goodwill impairment charge of $105.4 million and intangible asset impairment of $4.8 million were recognized in 2025.
• Professional services revenue decreased by 8% to $102.9 million in 2025, attributed to lower utilization rates, exit from unprofitable pilot Tech-Enabled Managed Services (TEMS), and churn of FTE-based arrangements.
• Dollar-based Retention Rate (Technology + TEMS) declined to 93% in 2025 from 102% in 2024, primarily due to churn and down-selling related to the migration of DOS clients to Ignite.
• Notified of approximately $12.5 million in DOS-related Annual Recurring Revenue (ARR) down-sell and churn expected to negatively impact 2026 and 2027 technology revenue.
• An estimated $52 million in DOS-related ARR, with approximately $35 million from data platform infrastructure, may be subject to negotiation in 2026 and 2027.
• The company incurred significant restructuring costs in 2025 ($9.7 million), 2024 ($2.1 million), and 2023 ($8.8 million) due to workforce reductions.
• Cash, cash equivalents, and short-term investments decreased significantly to $95.7 million as of December 31, 2025, from $392.0 million as of December 31, 2024.
• Interest and other (expense) income, net, decreased by $17.0 million in 2025, primarily due to a $7.1 million increase in interest expense and a $10.4 million decrease in interest income.

Risks

• Operating in a highly competitive industry with rapidly changing technologies and evolving regulatory requirements.
• Inability to successfully execute growth initiatives, business strategies, or cost reduction and restructuring initiatives, including the migration of DOS clients to Health Catalyst Ignite.
• Macroeconomic challenges (high inflation, high interest rates, tariffs, cuts in Medicaid and research funding, regional/global conflicts) could harm business, results of operations, and financial condition.
• Failure to innovate and provide useful services could lead to loss of competitiveness and revenue.
• Client dissatisfaction with the cloud-based data platform, software analytics applications, and expertise.
• Existing clients not renewing contracts, renewing at lower fee levels, or declining additional purchases.
• Information technology system failures, cyberattacks, or cybersecurity deficiencies.
• Actual or perceived failures to comply with data protection, privacy, and security laws.
• Dependence on third parties for data sourcing, with risks of blocked access or increased fees.
• Fluctuations in results of operations, potentially failing to meet analyst/investor expectations.
• Exposure to interest rate risks and restrictive covenants from the term loan facility.
• Pricing changes over time and ability to efficiently price solutions.
• Liability exposure if the solution fails to provide accurate information or is associated with faulty clinical decisions.
• Increasing reliance on AI and machine learning technologies may expose the company to significant risks, including development/deployment challenges, regulatory uncertainties, and third-party claims.
• Intense competition for highly skilled employees, potentially impacting ability to attract and retain talent.
• Reliance on third-party providers (e.g., Microsoft Azure) for computing infrastructure, with risks of disruption.
• Failure by clients to obtain proper permissions and waivers for data use.
• Volatility and potential decline in the market price of common stock.
• Potential for future litigation, which could be costly and time-consuming.
• Deriving a significant portion of revenue from largest clients, with risks of loss or renegotiation.
• Delays in reflecting business downturns due to ratable revenue recognition.
• Inability to implement and maintain effective internal controls over financial reporting.
• Difficulties in integrating acquired companies or technologies.
• Changes in laws and regulations related to the Internet or access to the Internet.
• Risks associated with open-source software licenses.
• Inability to maintain licenses for third-party software components.
• Failure to protect intellectual property rights.
• Being sued by third parties for alleged infringement of proprietary rights.
• Government regulation of healthcare creating compliance risks and challenges.
• Arrangements with clinicians potentially constituting improper rendering of professional medical services or fee splitting.
• FDA modifying enforcement policies for medical software products.
• Uncertain and evolving healthcare regulatory and political framework, including impacts from the One Big Beautiful Bill Act (OBBBA).
• Exposure to antitrust laws, Foreign Corrupt Practices Act (FCPA), foreign anti-bribery laws, and export controls.
• Taxing authorities asserting collection of sales and use, value-added, or similar transactional taxes.
• Unanticipated changes in effective tax rate and additional tax liabilities.
• Limitations on the ability to use net operating losses (NOLs) to offset future taxable income.
• Comprehensive tax reform legislation could adversely affect business and financial condition.
• Investors' expectations regarding environmental, social, and governance factors imposing additional costs and risks.

Future Outlook

The company anticipates slower near-term revenue growth due to policy developments around Medicaid and research funding reductions, which will financially strain clients. It expects a higher proportion of gross bookings from its existing client base. The migration of DOS clients to Health Catalyst Ignite will continue to impact technology revenue, with an increasing number of clients opting for price reductions. The company expects further churn of DOS-related ARR beyond the $12.5 million already identified for 2026 and 2027, with up to $52 million subject to negotiation, primarily from data platform infrastructure. Management expects to be through the data platform infrastructure migration headwind after 2027. The strategic operating plan focuses on cost efficiency, clinical improvement, and consumer experience, with continued investments in R&D to enhance Health Catalyst Ignite capabilities. Annual Adjusted EBITDA is expected to continue to improve, though at a slower rate in the near term.

Management Comments

• "We envision a future where all healthcare decisions are data-informed."
• "Team member engagement is foundational to everything we do and is a high priority of our CEO and broader leadership team."
• "When team members feel connected to our mission and are listened to, cared for, and respected at an extraordinary level, they produce outstanding work, which enables our clients to measurably improve."
• "We were encouraged that, in general, the operating margins of our health system end market improved in 2024 and 2025 relative to 2022 and 2023."
• "We have collected data internally that shows we are more than twice as effective at selling into organizations where we have an existing relationship compared to those where there is no prior relationship, which gives us additional confidence in our ability to drive cross-selling within our broad client base."
• "We have observed that clients have a few options as part of this migration [DOS to Ignite]... in recent months and in the near-term, an increasing number of clients are opting for, and we anticipate many will opt for, a price reduction as part of the migration to Ignite resulting in lower overall spend."
• "We are responding to the challenging macroeconomic environment with a strategic operating plan that proactively tailors our solutions to align with and support the urgent needs for cost efficiency, clinical improvement, and consumer experience."
• "Our priorities going forward will include strengthening and simplifying our commercial engine to drive technology ARR bookings, improving retention through more predictable migrations and clearer client value realization, and increasing efficiency and reducing time to value by eliminating operational complexity and scaling work through automation and global resources."
• "We are committed to providing more flexibility and meeting clients where they are and we expect this approach will improve client experience and our Dollar-Based Retention Rate."

Industry Context

StockSavvy.ai notes that Health Catalyst operates in a healthcare industry characterized by significant waste, changing economics, and increasing data complexity. The company's focus on cloud-based data and analytics platforms, software applications, and expertise aligns with the broader industry trend towards digital transformation and data-driven decision-making in healthcare. The macroeconomic challenges, including high inflation and interest rates, and cuts in Medicaid and research funding, are placing significant budgetary strain on healthcare providers, which directly impacts demand for solutions like Health Catalyst's. The company's strategy to tailor solutions for cost efficiency and clinical improvement directly addresses these urgent industry needs. The competitive landscape includes large industry-agnostic analytics companies (IBM, Databricks, Snowflake, Microsoft), EHR companies (Oracle Health, Epic Systems), and niche point solution vendors, highlighting the need for continuous innovation and differentiation. The increasing reliance on AI and machine learning in healthcare, as noted by Health Catalyst's investments in Healthcare.AI, reflects a key industry trend, albeit one that introduces new regulatory and ethical risks.

Comparison to Industry Standards

• The company mentions that its KLAS Overall Customer Satisfaction Scores have often historically been among the highest in the peer group, and its Chargemaster Management product (from the Vitalware acquisition) has been ranked Best in KLAS in multiple years, suggesting strong product and service quality compared to competitors.
• The Dollar-based Retention Rate (Tech + TEMS) of 93% for 2025, while a decline from 102% in 2024, indicates a challenge in client retention and expansion, particularly during the DOS to Ignite migration. This metric would need to be benchmarked against industry averages for similar healthcare SaaS providers to fully assess its competitiveness.
• The significant net loss and goodwill impairment in 2025, while partly due to non-cash items and restructuring, suggest underperformance relative to growth expectations and potentially compared to more profitable peers in the healthcare technology sector.
• The company's strategy of acquiring companies like Upfront, Intraprise, Lumeon, and Carevive to expand its product portfolio is a common industry practice for growth and market share expansion, similar to how larger players like Optum Analytics or IBM might integrate solutions. However, the integration costs and potential for lower retention rates from acquired clients (e.g., Medicity) highlight common challenges in M&A.

Management Changes

Corporate Governance

Legal Proceedings

• Settled a complaint filed by Pascal Metrics, Inc. in the Delaware Chancery Court on June 15, 2023, for $18.8 million, without admission of wrongdoing, resolving allegations of misappropriating trade secrets related to Patient Safety Monitor. The complaint was dismissed with prejudice on June 20, 2023.

Related Party Transactions

• Recognized revenue of $17.7 million from Carle Health for the year ended December 31, 2025, a client where a member of their executive leadership team began serving on Health Catalyst's board of directors effective July 1, 2023.
• As of December 31, 2025, had receivables of $1.7 million and deferred revenue of $0.2 million with Carle Health.

Stakeholder Impact

• Shareholders: Significant net loss and goodwill impairment could negatively impact share price and investment value. Dilution risk from future equity issuances for financings or acquisitions. Share repurchase plan aims to enhance value but may increase volatility.
• Employees (Team Members): Restructuring plans (January 2025, August 2025) resulted in global workforce reductions (4% and 9% respectively), potentially impacting morale, increasing attrition, and affecting future recruitment. However, the company emphasizes team member engagement and competitive compensation/benefits.
• Clients: Ongoing migration from DOS to Health Catalyst Ignite may lead to client dissatisfaction, churn, or down-selling, but the company aims for improved client experience and retention through a more client-centric approach and enhanced platform capabilities.
• Creditors: The Term Loan Facility exposes the company to interest rate risks and restrictive covenants, which could limit operational flexibility. However, the company was in compliance with all covenants as of December 31, 2025.
• Suppliers/Vendors: Reliance on third-party providers for computing infrastructure (e.g., Microsoft Azure) and data sourcing means disruptions or changes in terms from these parties could impact operations.

Next Steps

• Continue to manage the business with a focus on operating efficiency and targeted investments for disciplined growth and retention.
• Strengthen and simplify the commercial engine to drive technology ARR bookings.
• Improve retention through more predictable migrations and clearer client value realization.
• Increase efficiency and reduce time to value by eliminating operational complexity and scaling work through automation and global resources.
• Better leverage intellectual property, combining data foundation with expertise, content, and AI-enabled solutions.
• Continue to refine the strategic operating plan and make investments in research and development, particularly for Health Catalyst Ignite.
• Monitor implications of policy developments around Medicaid and research funding reductions, and the evolving tariff landscape.
• Complete remaining DOS client migrations to Health Catalyst Ignite, with meaningful progress anticipated by the end of the first half of 2026.
• Evaluate the provisions of ASU 2024-03 and ASU 2025-06 to determine their impact on consolidated financial statements and disclosures.
• File Form 10-K/A for the 2026 Annual Meeting of Stockholders within 120 days of December 31, 2025.

Key Dates

Recommendation

Health Catalyst is navigating a complex period marked by significant non-cash impairment charges and a decline in its Dollar-based Retention Rate, reflecting challenges in its platform migration and a tough macroeconomic environment. While Adjusted EBITDA shows operational improvement and technology revenue is growing, the substantial net loss and cash burn raise concerns. The company's strategic focus on cost efficiency, client retention, and R&D for its Ignite platform, coupled with recent acquisitions, indicates a long-term strategy to regain momentum. However, the near-term headwinds, particularly the anticipated DOS-related ARR down-sell and churn, suggest continued volatility. A seasoned investor would likely hold, awaiting clearer signs of successful platform migration, improved retention metrics, and sustained profitability before considering a stronger position.

Keywords

Healthcare analytics, Data platform, Cloud-based solutions, Health Catalyst Ignite, Patient engagement, Revenue cycle management, Population health, Cybersecurity, AI in healthcare, SEC filing, 10-K, Financial results, Goodwill impairment, Restructuring, Debt repayment, Acquisitions, Healthcare technology, Corporate governance, Risk management